MedTrace Logo

Study of Relationship Between Vedolizumab Therapeutic Drug Monitoring, Biomarkers of Inflammation and Clinical Outcomes

NCT04567628 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 7873

Last updated 2024-03-15

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if a relationship exists between Week 6 vedolizumab therapeutic drug monitoring (TDM) and Week 30 Faecal calprotectin (FCP).

Conditions

  • Inflammatory Bowel Diseases
  • Colitis, Ulcerative
  • Crohn Disease

Interventions

OTHER

No Intervention

As this was an observational study, no intervention was administered.

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Takeda

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-05
Primary Completion
2021-09-22
Completion
2021-09-22

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04567628 on ClinicalTrials.gov